Cargando…

KRAS and TP53 Mutations in Colorectal Carcinoma

Detalles Bibliográficos
Autor principal:	Al-Kuraya, Khawla S.
Formato:	Texto
Lenguaje:	English
Publicado:	Medknow Publications 2009
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2981835/ https://www.ncbi.nlm.nih.gov/pubmed/19794264 http://dx.doi.org/10.4103/1319-3767.56087

Ejemplares similares

Prevalence of germline TP53 mutation among early onset middle eastern breast cancer patients
por: Siraj, Abdul Khalid, et al.
Publicado: (2021)

KRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis
por: Du, Lijun, et al.
Publicado: (2017)

Mutational Analysis of KRAS, BRAF, and TP53 Genes of Ovarian Serous Carcinomas in Korean Women
por: Cho, Yun-Hyun, et al.
Publicado: (2009)

Recurrent, truncating SOX9 mutations are associated with SOX9 overexpression, KRAS mutation, and TP53 wild type status in colorectal carcinoma
por: Javier, Breanna M., et al.
Publicado: (2016)

KRAS, KIT and TP53 mutations in mother’s and daughter’s gastric cardia adenocarcinomas
por: Gluszek, Stanislaw, et al.
Publicado: (2018)

p53 pathway dysfunction in AML: beyond TP53 mutations
por: Post, Sean M., et al.
Publicado: (2017)

KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas
por: Gu, Meichen, et al.
Publicado: (2021)

Induction of pancreatic neoplasia in the KRAS/TP53 Oncopig
por: Mondal, Pinaki, et al.
Publicado: (2023)

Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations
por: Ruiz-Cordero, Roberto, et al.
Publicado: (2020)

TP53 /KRAS Co-Mutations Create Divergent Prognosis Signatures in Intrahepatic Cholangiocarcinoma
por: Guo, Chunguang, et al.
Publicado: (2022)

Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing
por: Sayed, Shady, et al.
Publicado: (2022)

TP53 mutations in Romanian patients with colorectal cancer
por: Manirakiza, Felix, et al.
Publicado: (2023)

Genomic landscape of pathogenic mutation of APC, KRAS, TP53, PIK3CA, and MLH1 in Indonesian colorectal cancer
por: Marbun, Vania Myralda Giamour, et al.
Publicado: (2022)

Unique volatolomic signatures of TP53 and KRAS in lung cells
por: Davies, M P A, et al.
Publicado: (2014)

Prognostic significance of TRAIL death receptors in Middle Eastern colorectal carcinomas and their correlation to oncogenic KRAS alterations
por: Bavi, Prashant, et al.
Publicado: (2010)

Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients
por: Fathi, Zahra, et al.
Publicado: (2018)

Modeling the prevalent germline TP53 R337H mutation in mouse
por: Park, Ji-Hoon, et al.
Publicado: (2019)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Genetic alterations of KRAS and TP53 in intrahepatic cholangiocarcinoma associated with poor prognosis
por: Peng, Jianbo, et al.
Publicado: (2023)

Transcriptional and functional consequences of TP53 splice mutations in colorectal cancer
por: Smeby, Jørgen, et al.
Publicado: (2019)

Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases
por: Løes, Inger Marie, et al.
Publicado: (2016)

Integrated single-cell RNA-seq analysis identifies immune heterogeneity associated with KRAS/TP53 mutation status and tumor-sideness in colorectal cancers
por: Liu, Xiaoyu, et al.
Publicado: (2022)

Analysis of Tp53 Codon 72 Polymorphisms, Tp53 Mutations, and HPV Infection in Cutaneous Squamous Cell Carcinomas
por: Loeb, Keith R., et al.
Publicado: (2012)

Expression of wild-type and mutated TP53 in breast carcinomas
por: Baumbusch, LO, et al.
Publicado: (2005)

Impact of KRAS Mutations on Management of Colorectal Carcinoma
por: Sullivan, Kevin M., et al.
Publicado: (2011)

KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer
por: Cicenas, Jonas, et al.
Publicado: (2017)

Survival Prediction of Patients Treated With Immune Checkpoint Inhibitors via KRAS/TP53/EGFR-Single Gene Mutation
por: Liu, Shui, et al.
Publicado: (2022)

TP53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma
por: Zhou, Yiran, et al.
Publicado: (2023)

Clinical, Pathological and Molecular Insights on KRAS, NRAS, BRAF, PIK3CA and TP53 Mutations in Metastatic Colorectal Cancer Patients from Northeastern Romania
por: Afrăsânie, Vlad-Adrian, et al.
Publicado: (2023)

Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma
por: Köbel, Martin, et al.
Publicado: (2016)

TP53 and MTOR crosstalk to regulate cellular senescence
por: Galluzzi, Lorenzo, et al.
Publicado: (2010)

Haploinsufficiency Interactions of RALBP1 and TP53 in Carcinogenesis
por: Awasthi, Sanjay
Publicado: (2021)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

MMP7 Polymorphisms - A New Tool in Molecular Pathology to Understand Esophageal Cancer
por: Bavi, Prashant P., et al.
Publicado: (2011)

Mutation analysis of P73 and TP53 in Merkel cell carcinoma
por: Gele, M Van, et al.
Publicado: (2000)

TP53 gene mutations and protein accumulation in primary vaginal carcinomas.
por: Skomedal, H., et al.
Publicado: (1995)

The prognostic value of TP53 mutations in hypopharyngeal squamous cell carcinoma
por: Omura, Go, et al.
Publicado: (2017)

Choroid Plexus Carcinomas With TP53 Germline Mutations: Management and Outcome
por: Li, Yanong, et al.
Publicado: (2021)

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
por: Li, Xuerui, et al.
Publicado: (2020)

Frequent Mutations in EGFR, KRAS and TP53 Genes in Human Lung Cancer Tumors Detected by Ion Torrent DNA Sequencing
por: Cai, Xin, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_3vjlgd7oerb91h3nceg1bn59us